SCHEMBL181292

SCHEMBL181292

Cc1ccc(S(=O)(=O)OC2CCOC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.52
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 3/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.40
CFTR P13569 1/20 0.39
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ACHE P22303 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
MMP13 P45452 2/20 0.36
MMP1 P03956 1/20 0.36
HTT P42858 1/20 0.36
HTR6 P50406 1/20 0.36
ENPP3 O14638 1/20 0.36
ENPP1 P22413 1/20 0.36
ENPP2 Q13822 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL507364 1.00 CYP2D6 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL506784 1.00 CYP2D6 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL25859829 0.91 CYP2D6 (0.50) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL21488522 0.91 CYP2D6 (0.50) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL435571 0.90 CYP2D6 (0.58) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL4641154 0.90 CYP2D6 (0.51) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL25173913 0.90 CYP2D6 (0.49) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL181141 0.87 CYP2D6 (0.54) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL29656200 0.86 CYP2D6 (0.51) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL21036753 0.84 TSHR (0.38) CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 US disclosed
US-20260132147-A1 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIV (US) 2026-05-14 US disclosed
EP-4737453-A1 NOVEL SELENOPHENE DERIVATIVES Aigen Sciences Inc. (KR) 2026-05-06 EP disclosed
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 US disclosed
US-20260103463-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-04-16 US disclosed
US-20260055105-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-02-26 US disclosed
US-20260008760-A1 DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF INSMED INCORPORATED 2026-01-08 US disclosed
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-12479857-B2 Bax inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2025-11-25 US disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
US-6051718-A A PHOSPHODIESTERASE ENZYME INHIBITOR AND A CYTOKINE ANTAGONIST FOR TREATING ALLERGIC, ATOPIC AND INFLAMMATORY DISEASES INFLAMMATORY DISEASES JANSSEN PHARMACEUTICA, N.V. (BE) 2000-04-18 US disclosed
WO-2000017203-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-03-30 WO disclosed
EP-0934280-A1 PDE IV INHIBITING 2-CYANOIMINOIMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-08-11 EP disclosed
WO-1998014432-A1 PDE IV INHIBITING 2-CYANOIMINOIMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1998-04-09 WO disclosed
US-5614527-A NITROGUANIDINE COMPOUND MITSUI TOATSU CHEMICALS, INC. (JP) 1997-03-25 US disclosed
US-4702763-A Herbicidal 1-aryl-delta2-1,2,4-triazolin-5-ones FMC CORPORATION (US) 1987-10-27 US disclosed
EP-0221083-A1 HALOALKYL TRIAZOLINONES FMC Corporation (US) 1987-05-13 EP disclosed
WO-1986004481-A2 HALOALKYL TRIAZOLINONES FMC CORPORATION (US) 1986-08-14 WO disclosed
EP-0157876-A1 HERBICIDAL 1-ARYL-$g(D)?2 -1,2,4-TRIAZOLIN-5-ONES FMC Corporation (US) 1985-10-16 EP disclosed
WO-1985001637-A1 HERBICIDAL 1-ARYL-DELTA2-1,2,4-TRIAZOLIN-5-ONES FMC CORPORATION (US) 1985-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE KIF2C, KIF5B, KIF5C CYP2D6 3826/4885CYP1A2 2815/4885CYP3A4 4182/4885
US-20260132147-A1 BAX INHIBITORS AND USES THEREOF BAX, BCL2, BAK1 CYP2D6 1953/4885CYP1A2 3876/4885CYP3A4 2220/4885
US-20260008760-A1 DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF DPP9, DPP7, DPP4 CYP2D6 79/4885CYP1A2 1328/4885CYP3A4 434/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK CYP2D6 4346/4885CYP1A2 4463/4885CYP3A4 4471/4885
US-20260103463-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR CYP2D6 813/4885CYP1A2 2001/4885CYP3A4 1988/4885
US-20260055105-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GIPR, GPR119 CYP2D6 1965/4885CYP1A2 2778/4885CYP3A4 2193/4885
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX7 CYP2D6 1148/4885CYP1A2 877/4885CYP3A4 1652/4885
US-12479857-B2 Bax inhibitors and uses thereof BAX, TMBIM6, BCL2 CYP2D6 3948/4885CYP1A2 4295/4885CYP3A4 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.